Connect Meaningfully with Senior MASH BioPharma Leaders
The 10th MASH Drug Development Summit is the industry's leading forum for connecting with the decision-makers driving the next generation of MASH therapies. Join leaders from Pfizer, Madrigal, Novo Nordisk, Insitro, Takeda, and other pioneering biopharma companies as they seek innovative partners to advance non-invasive and reproducible endpoints, implement novel clinical trial endpoints, and leverage AI-powered digital pathology solutions.
This is your opportunity to engage directly with the companies shaping the future of MASH drug development, showcase your expertise, and position your organisation as a partner of choice in this rapidly evolving market.
Showcase your biomarker, diagnostic or AI-enabled pathology solutions
Showcase to developers seeking to improve patient stratification, strengthen endpoint interpretation and reduce reliance on liver biopsy, demonstrating how your technologies can accelerate decision-making and improve clinical trial efficiency
Position your preclinical, translational and discovery platforms as essential tools for improving clinical predictability
Therefore, helping drug developers reduce translational risk, strengthen target validation and identify the most promising therapeutic candidates earlier in development
Demonstrate your clinical development, regulatory or CRO expertise
Demonstrate to organizations navigating evolving standards of care, non-invasive endpoints and increasingly complex trial designs, establishing your company as a trusted partner for efficient MASH development
Connect directly with decision-makers developing next-generation therapies
Including combination approaches, anti-fibrotic mechanisms, precision medicine strategies and advanced fibrosis programs, showcasing how your solutions can accelerate development and improve the likelihood of clinical and commercial success
Available Inventory
We have a range of inventory from standard booth and speaking slots to more bespoke deliverable such as exclusive dinners to help elevate your brand.
Presenting Slots
Data-driven or case study-led presentations to position yourself as a thought-leader.
Leading Innovation
Expert panels to shape forward-thinking discussions.
Full Delegate List
Gain exclusive access to the Full Delegate List to plan your conversations in advance.
Exhibiting
Raise brand awareness and answer questions from prospect customers.
Networking
Engage in 1-2-1 conversations with industry or be part of the organized networking options to generate commercial collaborations.
Bespoke Hosting
Host breakfast, lunches, dinners for drinks receptions to have exclusive time with your target audience.
Champion the Industry
Be part of the RAS community and position yourself as an advocate for innovation and achievements in the RAS-targeted therapeutics space.
Branding
On-site and website branding to highlight your company at the forefront of the RAS field.
Key Services & Solutions in Demand
Biomarkers & Diagnostics:
Support the shift beyond liver biopsy with non-invasive biomarker, diagnostic, and endpoint solutions that improve patient identification, monitor treatment response, and enable more efficient clinical development. As the MASH field advances toward scalable and reproducible endpoints, these providers are helping sponsors de-risk trials, accelerate timelines, and bring therapies to market faster.
AI Pathology & Digital Health:
As MASH developers seek more reproducible and data-driven approaches to endpoint assessment, AI-powered pathology and digital analytics platforms are becoming increasingly critical. These providers help reduce inter-observer variability, improve fibrosis and inflammation assessment, and enable faster, more informed development decisions across the clinical pipeline.
Preclinical & Translational Models:
As MASH pipelines become increasingly competitive, robust preclinical models becoming mor critical. Biopharma is seeking partners that provide advanced in vitro, in vivo, and ex vivo platforms that improve translational relevance, support mechanism validation, and help sponsors make more confident go/no-go decisions before entering the clinic.
Audience Composition
Company Type
Attendee Seniority
Attending Companies Include